Charles River Laboratories International, Inc. (NYSE:CRL) is set to announce its earnings results before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of $1.22 per share for the quarter. Charles River Laboratories International has set its FY17 guidance at $5.00-5.15 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same period in the previous year, the business posted $1.20 EPS. Charles River Laboratories International’s revenue was up 8.1% on a year-over-year basis. On average, analysts expect Charles River Laboratories International to post $5.1 EPS for the current fiscal year and $5.63 EPS for the next fiscal year.

Charles River Laboratories International, Inc. (CRL) opened at 116.29 on Wednesday. The stock has a 50 day moving average of $110.71 and a 200 day moving average of $100.54. The firm has a market capitalization of $5.53 billion, a price-to-earnings ratio of 30.64 and a beta of 0.96. Charles River Laboratories International, Inc. has a one year low of $67.20 and a one year high of $118.66.

In related news, insider David Ross Smith sold 2,552 shares of Charles River Laboratories International stock in a transaction on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the sale, the insider now owns 11,671 shares in the company, valued at $783,124.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider William D. Barbo sold 4,000 shares of Charles River Laboratories International stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the completion of the sale, the insider now owns 20,424 shares of the company’s stock, valued at approximately $2,040,561.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,699 shares of company stock valued at $1,892,393. Insiders own 2.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Scheduled to Post Quarterly Earnings on Wednesday” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/01/charles-river-laboratories-international-inc-crl-scheduled-to-post-quarterly-earnings-on-wednesday.html.

A number of research analysts have weighed in on CRL shares. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Robert W. Baird reissued a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. BidaskClub cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price on the stock. Finally, Credit Suisse Group reissued a “neutral” rating and set a $112.00 target price (up from $95.00) on shares of Charles River Laboratories International in a research report on Monday, October 16th. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $103.77.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.